All patients
Age < 65y (younger) Age > 65y Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), cemiplimab vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77]
0.63 [0.52 ; 0.77 ] EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021 2 0% 1,273 moderate not evaluable progression or deaths (PFS)detailed results EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68]
0.57 [0.49 ; 0.66 ] EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021 2 0% 1,273 moderate not evaluable objective responses (ORR)detailed results EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85]
2.27 [1.69 ; 3.07 ] EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021 2 0% 1,273 moderate not evaluable AE (any grade)detailed results EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
0.18 [0.12 ; 0.27 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
0.19 [0.13 ; 0.29 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable AE leading to death (grade 5)detailed results EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
1.24 [0.46 ; 3.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
1.62 [0.82 ; 3.21 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Colitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increase AST TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
3.87 [0.17 ; 86.12 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Rash TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
3.87 [0.17 ; 86.12 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Alopecia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Anaemia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.03 [0.01; 0.13]
0.03 [0.01 ; 0.13 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Arthralgia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Asthenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Back pain AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Constipation AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Decreased appetite AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
0.96 [0.06 ; 15.46 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Diarrhoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.16 [0.02; 1.32]
0.16 [0.02 ; 1.32 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Dyspnoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.17; 21.41]
1.93 [0.17 ; 21.41 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Fatigue AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.72 [0.16; 3.24]
0.72 [0.16 ; 3.24 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.06 [0.00; 1.03]
0.06 [0.00 ; 1.03 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Hypertension AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increase AST AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 4.87 [0.57; 41.91]
4.87 [0.57 ; 41.91 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increased ALT AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64]
5.82 [0.29 ; 116.64 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Leucopenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.10 [0.01; 0.83]
0.10 [0.01 ; 0.83 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable myocarditis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Nausea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.12 [0.01; 2.26]
0.12 [0.01 ; 2.26 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Neutropenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.05 [0.01; 0.21]
0.05 [0.01 ; 0.21 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pancytopenia (AE grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
0.96 [0.06 ; 15.46 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pneumonia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.77 [0.20; 2.88]
0.77 [0.20 ; 2.88 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pneumonitis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Rash AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64]
5.82 [0.29 ; 116.64 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Stomatitis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.02 [0.00; 0.30]
0.02 [0.00 ; 0.30 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Vomiting AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.12 [0.01; 2.26]
0.12 [0.01 ; 2.26 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Weight decreased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:11 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 1049